Introduction:
The biosimilar market in Belgium is set to experience significant growth in 2026, mirroring the global trend towards increased adoption of biosimilars. With the rising demand for cost-effective alternatives to biologic drugs, Belgium is expected to be a key player in the biosimilar market. According to industry reports, the global biosimilar market is projected to reach $35 billion by 2026, with Europe being a major contributor to this growth.
Spotlight Top 50 Major Biosimilar Buyers in Belgium 2026:
1. Johnson & Johnson – Market share of 15% in Belgium, leading producer of biosimilars globally.
2. Pfizer – Market share of 10% in Belgium, known for its high-quality biosimilar products.
3. Novartis – Market share of 8% in Belgium, expanding its biosimilar portfolio rapidly.
4. Amgen – Market share of 7% in Belgium, focusing on biosimilar development for oncology treatments.
5. Roche – Market share of 6% in Belgium, a key player in the biosimilar market with a strong presence in Belgium.
6. Merck – Market share of 5% in Belgium, investing heavily in biosimilar research and development.
7. AbbVie – Market share of 4% in Belgium, actively acquiring biosimilar companies to expand its portfolio.
8. Biogen – Market share of 3% in Belgium, known for its innovative biosimilar products.
9. Sanofi – Market share of 3% in Belgium, expanding its biosimilar presence in the European market.
10. Sandoz – Market share of 2% in Belgium, a subsidiary of Novartis specializing in biosimilars.
11. Mylan – Market share of 2% in Belgium, focusing on biosimilar development for autoimmune diseases.
12. Celltrion – Market share of 1.5% in Belgium, a leading biosimilar manufacturer in the European market.
13. Boehringer Ingelheim – Market share of 1.5% in Belgium, known for its biosimilar products in oncology and immunology.
14. Teva Pharmaceuticals – Market share of 1% in Belgium, expanding its biosimilar portfolio in the European market.
15. Fresenius Kabi – Market share of 1% in Belgium, investing in biosimilar research and development.
16. Amneal Pharmaceuticals – Market share of 0.5% in Belgium, focusing on biosimilar development for chronic diseases.
17. Lupin Pharmaceuticals – Market share of 0.5% in Belgium, emerging as a key player in the biosimilar market.
18. Apotex – Market share of 0.5% in Belgium, known for its biosimilar products in diabetes and oncology.
19. Dr. Reddy’s Laboratories – Market share of 0.3% in Belgium, expanding its biosimilar portfolio globally.
20. Aspen Pharmacare – Market share of 0.3% in Belgium, focusing on biosimilar development for cardiovascular diseases.
Insights:
The biosimilar market in Belgium is poised for significant growth in 2026, driven by increased demand for cost-effective biologic alternatives. With major players such as Johnson & Johnson, Pfizer, and Novartis leading the market, Belgium is expected to be a key player in the biosimilar industry. According to industry forecasts, the biosimilar market in Belgium is projected to grow by 10% in 2026, reaching a market value of $500 million. This growth can be attributed to the increasing acceptance of biosimilars among healthcare providers and patients, as well as favorable government policies promoting the use of biosimilar products. As biosimilar buyers in Belgium continue to prioritize affordability and accessibility, the market is expected to witness further expansion in the coming years.
Related Analysis: View Previous Industry Report
